iCAN- Israel Cannabis and Breath of Life Pharma (BOL Pharma) announced a new partnership to form the first private cannabis R&D incubator center in Israel.
The primary objectives of the new center will be the research and development of new cannabis-related technologies with the goal of successful commercialization. The center will serve as an incubator for cannabis innovation as well as a validator for cannabis-based medicine, ag-tech and topical product development based on stringent scientific guidelines and standards.
Dr. Tamir Gedo, CEO of BOL Pharma said in a statement, “BOL greenhouses allow developers to use the professional services and knowledge of BOL Pharma, in order to produce strains, improve growing conditions, GAP, master extraction, formulation and production of materials under GMP conditions and ultimately to enable companies to commercialize their research and go to market. Together with iCAN- Israel Cannabis, we will incubate companies from all over the world to test and validate medical products for the Global Cannabis market.”
Saul Kaye, Founder and CEO of iCAN- Israel Cannabis said in a statement, “We are thrilled to partner with BOL Pharma and provide a global incubator and proving ground for Cannabis technology. We are confident our partnership will enable the most promising start-ups and innovators in Israel and abroad, to create world-class products for the Global Cannabis economy.”
The announcement took place at iCAN’s CannaTech International Summit for Accelerating Cannabis Innovation. CannaTech hosted over 400 guests in their three-day Summit, including scientists, researchers, investors and businessmen and women from more than 15 countries. They all gathered in Tel Aviv and Jerusalem to share their knowledge of various medical cannabis innovations and discuss investment opportunities.